Pharma & Biotech Global Week in Review 17 March 2010 from IP Think Tank

Here is IP Think Tank’s weekly selection of top Pharma & Biotech intellectual property news breaking in the blogosphere and internet.

Please join the discussion by adding your comments on any of these stories, and please do let us know if you think we’ve missed something important, or if there is a source you think should be monitored.

You can separately subscribe to the IP Think Tank Global Week in Review at the Subscribe page: http://thinkipstrategy.com/subscribe/

 
Highlights this week included:

US: CAFC affirms invalidity of Lysine-producing bacterium patents for lack of best mode: Ajinomoto v. ITC (Patent Baristas) (Holman’s Biotech IP Blog) (Patent Docs) (Patently-O)

 
General

Nanotechnology: Beyond the blockbuster (IP Osgoode)

Food and Agriculture Organisation conference draws ire from civil society; industry satisfied by event (IP Watch)

Some consideration of patents and traditional knowledge implications: The 2009 UN Report on the Status of Indigenous Peoples (IP Osgoode)

EU: European generics industry calls for ‘urgent patent reform’ (IP Watch)

EU: SPCs and RDP compared (SPC Blog)

EU: Patentability of biotech inventions in Europe – Lecture IV notes (SiNApSE)

Germany – SPC on the basis of an MA for active implantable medical devices (SPC Blog)

India: Delhi HC guidance on challenging pre-grant orders through writ petitions: UCB Farchim SA Vs. Cipla Ltd & Others (Spicy IP)

Indian civil society raises concerns over US industry-sponsored IP summits (IP Watch)

India: Making Patents Work – Feroz Ali (Spicy IP)

India: AIDS patients protest EU-India trade agreement (IP Watch)

India: Trade secrets and biotechnology – Lecture V notes (SiNApSE)

Mexico: Mexican Supreme Court confirms linkage is available for all product patents, including formulation patents (Olivares & CIA)

Poland: No hidden advertising of pharmaceuticals (Class 46)

Poland: Nuances in advertising of pharmaceutical products (Class 46)

US: Senator Landrieu introduces legislation (S 3089) requiring study on effects of first-to-file provision (Patent Docs)

US: Rep. Hinchey introduces the FDA Improvement Act of 2010; the Bill would unravel User Fee Legislation, among other changes (FDA Law Blog)

US: CAFC affirms invalidity of Lysine-producing bacterium patents for lack of best mode: Ajinomoto v. ITC (Patent Baristas) (Holman’s Biotech IP Blog) (Patent Docs) (Patently-O)

US: Boehringer Ingelheim seeks review and correction of the patent term adjustment calculation (Patent Docs)

US: District Court Columbia remands Pfizer PTA suit to USPTO (Patent Docs)

US: House Bill (HR 4808) seeks to codify President’s stem cell order (Patent Docs)

US: Utah passes nation’s first (?) Bioprospecting Regulation (Technology & Marketing Law Blog)

 
Products

Actoplus Met (Metformin and Pioglitazone) – US: Mylan announces first-to-file opportunity settlement agreements for Actoplus Met and Actos (SmartBrief)

Actos (Pioglitazone) – US: Ranbaxy announces settlement of Actos patent litigation against Takeda (SmartBrief) (patentcircle) (GenericsWeb)

Actos (Pioglitazone), Actoplus (Pioglitazone, Metformin) – US: FDA grants petition on Pioglitazone split certification issue; it’s caveat utilitor on old Orange Book patent listings (FDA Law Blog)

Angiomax (Bivalirudin) – US: PTO’s Angiomax PTE denial is vacated and the case goes back to PTO – what happens in the interim?: The Medicines Company v David Kappos et al (FDA Law Blog)

Advate (Antihemophilic) – US: False marking complaint filed in N D Illinois: Simonian v. Baxter Healthcare Corp. (Patent Docs)

Amevive (Alefacept) – US: False marking complaint filed in N D Illinois: Simonian v. Astellas Pharma US, Inc. (Patent Docs)

Aplenzin (Bupropion) – US: District Court Delaware: Patent infringement complaint filed following a Paragraph IV Certification: Biovail Laboratories International SRL v. Paddock Laboratories, Inc. (Patent Docs)

Atripla (Emtricitabine) – US: District Court S D New York: Patent infringement suit filed following a Paragraph IV Certification: Merck, Sharp & Dohme Corp. et al. v. Teva Pharmaceuticals USA, Inc. et al. and Gilead Sciences, Inc., et al. v. Teva Pharmaceuticals Industries Ltd. et al. (Patent Docs)

Avage, Tazorac (Tazarotene) – US: District Court N D Illinois: False marking complaint based on marking of Avage, Tazorac cream and Tazorac gel products: Simonian v. Allergan, Inc. (Patent Docs)

Cozaar (Losartan), Hyzaar (Hydrochlorothiazide, Losartan) – US: Court of Appeals for District of Columbia Circuit orders and declares that Teva has not forfeited 180-day exclusivity for Cozaar/Hyzaar (FDA Law Blog)

Eloxatin (Oxaliplatin) – US: Sanofi/Sun Deal over generic Eloxatin deemed enforceable (Patent Docs)

Ery Tab (Erythromycin) – US: District Court N D Illinois: False marking complaint over marking of Ery Tab product: Simonian v. Abbott Laboratories (Patent Docs)

Flomax (Tamsulosin) – US: The last shall be first… The case of generic Flomax – Hatch-Waxman backstory to approval of Impax first generic version of Boehringer Ingelheim’s Flomax (FDA Law Blog)

Focalin (Dexmethylphenidate), Ritalin (Methylphenidate) – US: Settlement in ADHD patent infringement suits announced – Celgene Corp. and Novartis AG against defendants KV Pharmaceutical Co. and IntelliPharmaCeutics Corp (Patent Docs) (GenericsWeb)

Neupogen (Filgrastim) – US: District Court N D Illinois: False marking complaint lodged based on marking of Neupogen product: Simonian v. Amgen, Inc. (Patent Docs)

Opana (Oxymorphone) – US: District Court New Jersey: Patent infringement complaint following a Paragraph IV Certification: Endo Pharmaceuticals Inc. et al. v. Watson Pharmaceuticals, Inc. et al (Patent Docs)

Plavix (Clopidogrel) Australia: High Court refuses application by Sanofi-Aventis for special leave to appeal decision finding its patent claiming salts of the isolated enantiomer of a known racemate was invalid for want of inventive step (IP Whiteboard)

Seasonique, LoSeasonique (Ethinyl estradiol, Levonorgestrel) – US: District Court New Jersey: Patent infringement complaints following a Paragraph IV Certification: Teva Women’s Health, Inc. v. Mylan Pharmaceuticals, Inc. et al. (Patent Docs) (GenericsWeb) (patentcircle)

Temodar (Temozolomide) – US: Teva announces parties to patent litigation regarding Barr’s US generic Temodar have entered into agreement pending resolution of Schering’s appeal to CAFC over ‘291 patent unenforceability finding (SmartBrief)

Trilipix (Fenofibrate) – US: Impax Laboratories confirms challenge to Abbott and Fournier’s listed patent relating to Trilipix delayed-release capsules, 135 mg and 45 mg (SmartBrief)

Zyprexa (Olanzapine) – Canada: Novopharm says Eli Lilly Canada may become judgment-proof, abandon Canada (GenericsWeb)

 

Leave a Reply

Fill in your details below or click an icon to log in:

WordPress.com Logo

You are commenting using your WordPress.com account. Log Out / Change )

Twitter picture

You are commenting using your Twitter account. Log Out / Change )

Facebook photo

You are commenting using your Facebook account. Log Out / Change )

Google+ photo

You are commenting using your Google+ account. Log Out / Change )

Connecting to %s

%d bloggers like this: